{"gene":"GNA11","run_date":"2026-06-10T01:55:21","timeline":{"discoveries":[{"year":2010,"finding":"Somatic mutations at Q209 and R183 in GNA11 (encoding Gα11, an alpha subunit of heterotrimeric G proteins) constitutively activate the MAPK pathway and induce spontaneously metastasizing tumors in a mouse model, establishing GNA11 as an oncogene in uveal melanoma.","method":"Sequencing of melanocytic neoplasms, mouse model with GNA11-mutant expression, MAPK pathway activation assay","journal":"The New England journal of medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — mutant gene expression in mouse model with defined phenotypic readout (metastasizing tumors) and MAPK pathway activation, replicated across multiple labs in subsequent work","pmids":["21083380"],"is_preprint":false},{"year":2013,"finding":"PKC activation is a consequence of GNAQ or GNA11 mutation in uveal melanoma, and PKC inhibition suppresses both PKC and MAPK signaling, establishing PKC as a key effector downstream of mutant GNA11. PKC inhibitors alone cannot sustain MAPK suppression, but combined PKC + MEK inhibition produces synergistic anti-tumor effects in vitro and in vivo.","method":"Cell line signaling assays with PKC inhibitors (AEB071, AHT956) and MEK inhibitors (PD0325901, MEK162), allograft and xenograft mouse models","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (in vitro signaling, in vivo xenograft), consistent findings across multiple inhibitors and models","pmids":["24141786"],"is_preprint":false},{"year":2016,"finding":"In vitro expression of mutant GNA11(R183C) activates the p38 MAPK signaling pathway, while GNA11(Q209L) activates p38, JNK, and ERK pathways, demonstrating differential downstream signaling depending on mutation site. Mosaic zebrafish expressing GNA11(R183C) under the mitfa promoter develop extensive dermal melanocytosis.","method":"In vitro expression of mutant GNA11 in human cell lines, transgenic zebrafish model","journal":"The Journal of investigative dermatology","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct functional assays in human cell lines plus in vivo zebrafish model with specific phenotypic readout, multiple orthogonal methods","pmids":["26778290"],"is_preprint":false},{"year":2014,"finding":"A germline gain-of-function mutation in GNA11 (R60L) causes autosomal dominant hypoparathyroidism. Functional studies in HEK293 cells stably expressing CaSR showed that R60L Gα11 increases intracellular calcium accumulation in response to extracellular calcium with a significantly decreased EC50, indicating enhanced coupling of the calcium-sensing receptor to Gα11 signaling. R60L was less effective than oncogenic Q209L as an activator of the MAPK pathway.","method":"Whole-exome sequencing, functional expression of wild-type and mutant Gα11 in HEK293-CaR cells, intracellular calcium measurement","journal":"The Journal of clinical endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct in vitro functional assay with mutant vs. wild-type comparison in CaSR-expressing cells, single lab but multiple parameters measured","pmids":["24823460"],"is_preprint":false},{"year":2016,"finding":"A loss-of-function GNA11 mutation (Thr54Met), located at the interface between the Gα11 helical and GTPase domains, impairs GDP binding and interdomain interactions. Expression in HEK293 cells stably expressing CaSR demonstrated rightward shift of the calcium concentration-response curve (increased EC50), establishing loss-of-function as the mechanism for FHH2.","method":"Homology modeling, functional expression in HEK293-CaSR cells, flow cytometry for intracellular calcium measurement","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — structural modeling plus in vitro functional assay with mutant vs. wild-type, single lab with multiple orthogonal methods","pmids":["26729423"],"is_preprint":false},{"year":2017,"finding":"A loss-of-function GNA11 mutation (Phe220Ser) disrupts a hydrophobic cleft region of Gα11 that is critical for binding to and activating phospholipase C (PLC). Expression of mutant Gα11 in CaSR-expressing HEK293 cells impaired CaSR-mediated intracellular calcium and ERK1/2 MAPK signaling. Engineered mutagenesis of the hydrophobic cleft confirmed its role in PLC activation. The loss-of-function was rescued by cinacalcet (a CaSR-positive allosteric modulator) both in vitro and in vivo.","method":"Homology modeling, transient transfection of mutant vs. wild-type Gα11 in HEK293-CaSR cells, calcium signaling assay, ERK phosphorylation assay, site-directed mutagenesis, in vivo cinacalcet treatment","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 1 / Strong — structural modeling + mutagenesis + in vitro reconstitution + in vivo validation, multiple orthogonal methods in single rigorous study","pmids":["28833550"],"is_preprint":false},{"year":2018,"finding":"GNA11(Q209L) mouse model (melanocyte-specific expression) develops uveal melanoma-like pigmented neoplastic lesions from melanocytes in the eye, skin, leptomeninges, lymph nodes, and lungs. Transcriptome analysis identified RasGRP3 as specifically expressed in GNAQ/GNA11-driven melanomas; RasGRP3 is required for GNAQ/GNA11-driven Ras activation and tumorigenesis in human UM cell lines and murine models.","method":"Transgenic mouse model (GNA11Q209L melanocyte-specific), integrative transcriptome analysis, RasGRP3 knockdown in human UM cell lines and murine models","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic model plus loss-of-function in human cell lines with defined molecular readout (Ras activation), multiple orthogonal methods","pmids":["29490280"],"is_preprint":false},{"year":2018,"finding":"GNA11 knockdown in human fetoplacental endothelial cells (HUVECs under 3% O2) significantly reduces FGF2- and VEGFA-stimulated cell migration but not proliferation or permeability. GNA11 siRNA also elevated FGF2- and VEGFA-induced phosphorylation of phospholipase C-β3 (PLCβ3) at S537, indicating that GNA11 mediates FGF2/VEGFA-induced endothelial migration partly by modulating PLCβ3 activation.","method":"siRNA knockdown of GNA11 in HUVECs, cell migration assay, phospho-PLCβ3 and phospho-ERK1/2 immunoblotting","journal":"The Journal of physiology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — siRNA knockdown with defined cellular phenotype (migration) and molecular readout (PLCβ3 phosphorylation), single lab, two orthogonal readouts","pmids":["29659033"],"is_preprint":false},{"year":2021,"finding":"Somatic gain-of-function mutations of GNA11 (Q209H, Q209P, Q209L) co-occur with CTNNB1 mutations in aldosterone-producing adenomas (APAs). Transfections of adrenocortical cells demonstrated additive effects of GNA11 and CTNNB1 mutations on aldosterone secretion and expression of genes upregulated in double-mutant APAs, including LHCGR.","method":"Whole-exome sequencing, targeted sequencing, transfection of adrenocortical cells with mutant constructs, aldosterone secretion assay, gene expression analysis","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vitro functional transfection assays showing additive effects on aldosterone secretion, multiple methods and cohort-level validation","pmids":["34385710"],"is_preprint":false},{"year":2023,"finding":"Disease-causing GNAQ/GNA11 mosaic variants hyperactivate constitutive and ligand-induced intracellular calcium signaling in endothelial cells. The aberrant ligand-activated calcium signal is fueled by extracellular calcium influx through calcium-release-activated (CRAC) channels. siRNA silencing of the variant allele corrects both signals; a CRAC channel inhibitor rescues the ligand-activated signal.","method":"Two cellular models of GNAQ/GNA11 mosaicism, calcium signaling assays, allele-specific siRNA, CRAC channel inhibitor treatment","journal":"The Journal of investigative dermatology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal interventions (allele-specific siRNA, small molecule inhibitor), two cellular models, defined molecular mechanism identified","pmids":["37802293"],"is_preprint":false},{"year":2024,"finding":"INPP5A is a synthetic lethal dependency in GNAQ/GNA11-mutant uveal melanoma cells. Mutant GNA11/GNAQ cells constitutively produce high levels of IP3; suppression of INPP5A causes IP3 accumulation, hyperactivation of IP3-receptor signaling, increased cytosolic calcium, and p53-dependent apoptosis. GNA11/GNAQ inhibition abolishes elevated IP4 levels (a biomarker of IP3 production) and correlates with INPP5A sensitivity.","method":"Genome-scale CRISPR screens, computational cancer dependency analyses, INPP5A knockdown in UM cell lines and in vivo, IP3/IP4 measurement, calcium assay, p53-dependent apoptosis assay","journal":"Nature cancer","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-scale CRISPR screen plus in vitro and in vivo validation with defined molecular mechanism (IP3-receptor-Ca2+-p53 axis), multiple orthogonal methods","pmids":["38233483"],"is_preprint":false},{"year":2014,"finding":"YAP (Yes-associated protein) inhibition with verteporfin blocks tumor growth of Gq/11-mutated uveal melanoma cells, implicating the Hippo/YAP pathway as a downstream effector of mutant GNA11/GNAQ.","method":"YAP inhibitor (verteporfin) treatment of GNA11/GNAQ-mutant UM cells, tumor growth assay","journal":"Molecular & cellular oncology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — pharmacological inhibition of downstream effector with tumor growth readout, limited mechanistic dissection, single method","pmids":["27308390"],"is_preprint":false},{"year":2013,"finding":"The GNA11 promoter contains a functional binding site for the transcription factor Egr-1 at nt-475/-445. Egr-1 expression increases GNA11 promoter activity >2-fold and elevates Gα11 mRNA levels, establishing Egr-1 as a transcriptional regulator of GNA11.","method":"Promoter cloning, luciferase reporter assay with deletion constructs, electrophoretic mobility shift assay (EMSA), Egr-1 expression plasmid transfection, real-time PCR","journal":"Basic & clinical pharmacology & toxicology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA plus reporter assay plus mRNA quantification, single lab, multiple orthogonal methods","pmids":["23802749"],"is_preprint":false},{"year":1996,"finding":"Murine Gna11 and Gna15 are tandemly duplicated genes on mouse chromosome 10, spanning 43 kb with 6 kb intergenic region. The coding sequence of Gna11 is contained in seven exons with no evidence for alternative splicing. Gna11 is ubiquitously expressed, whereas Gna15 is restricted to hematopoietic cells.","method":"Gene structure characterization, genomic DNA sequencing, expression analysis, phylogenetic analysis","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct genomic characterization with expression analysis across tissues, single lab but foundational structural characterization","pmids":["8838318"],"is_preprint":false},{"year":2014,"finding":"GNA11-encoded Gα11 couples the calcium-sensing receptor (CaSR) to phospholipase C (PLC)-mediated intracellular calcium signaling and MAPK signaling in parathyroid cells and kidneys to regulate PTH release and urinary calcium excretion. Loss-of-function mutations in Gα11 result in familial hypocalciuric hypercalcemia type 2 (FHH2).","method":"Genetic sequencing, functional expression in HEK293-CaSR cells, intracellular calcium assay, ERK signaling assay","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 2 / Strong — functional coupling of CaSR-Gα11-PLC-calcium axis demonstrated in multiple FHH2 mutation studies with consistent results across multiple labs","pmids":["26729423","28833550","24823460"],"is_preprint":false},{"year":2022,"finding":"GNAQ and GNA11 proteins have different protein interaction partners as determined by tandem-affinity-purification and mass spectrometry. Specifically, TET2 (Tet Methylcytosine Dioxygenase 2, a DNA demethylation enzyme) physically interacts with GNAQ but not with GNA11, as confirmed by immunoprecipitation, suggesting differential regulation of DNA methylation by the two G-proteins.","method":"Tandem-affinity-purification, mass spectrometry, immunoprecipitation","journal":"European journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP plus mass spectrometry interactome, single lab, two orthogonal methods supporting differential binding","pmids":["35580369"],"is_preprint":false},{"year":2014,"finding":"GNA11-mutant uveal melanoma cells show activation of both PKC/MAPK and PI3K/AKT pathways downstream of mutant GNAQ/GNA11. Reciprocal activation of MAPK and AKT is observed upon MEK or PI3K inhibition, respectively. Combined MEK + PI3K inhibition induces apoptosis in a GNAQ/11 mutant-dependent manner.","method":"RNA interference, MEK inhibitor (GSK1120212) and PI3K inhibitor (GSK2126458) treatment, proteomic network analysis, apoptosis assay in genotyped UM cell lines","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNAi plus pharmacological inhibition with proteomic analysis, multiple cell lines with defined mutation status","pmids":["22733540"],"is_preprint":false}],"current_model":"GNA11 encodes Gα11, a ubiquitously expressed alpha subunit of heterotrimeric Gq-class G proteins that couples the calcium-sensing receptor (and other GPCRs) to phospholipase C-β, generating IP3 and DAG to activate intracellular calcium signaling, PKC/MAPK, PI3K/AKT, and YAP pathways; somatic gain-of-function mutations at Q209 or R183 constitutively activate these cascades to drive uveal melanoma and vascular tumors via RasGRP3-mediated Ras activation and INPP5A-regulated IP3/calcium homeostasis, while germline loss-of-function mutations impair CaSR-Gα11-PLC coupling to cause familial hypocalciuric hypercalcemia type 2 (FHH2) and germline gain-of-function mutations cause autosomal dominant hypocalcemia type 2 (ADH2)."},"narrative":{"mechanistic_narrative":"GNA11 encodes Gα11, a ubiquitously expressed alpha subunit of a heterotrimeric Gq-class G protein that couples the calcium-sensing receptor (CaSR) and other GPCRs to phospholipase C, driving intracellular calcium and MAPK signaling [PMID:8838318, PMID:26729423, PMID:28833550, PMID:24823460]. Through a hydrophobic cleft required for PLC binding and activation, Gα11 transduces CaSR signaling in parathyroid and kidney cells to control PTH release and urinary calcium excretion; loss-of-function mutations (Thr54Met, Phe220Ser) shift the calcium response curve rightward and cause familial hypocalciuric hypercalcemia type 2, while a gain-of-function mutation (R60L) lowers the EC50 for calcium and causes autosomal dominant hypoparathyroidism [PMID:24823460, PMID:26729423, PMID:28833550]. Somatic gain-of-function mutations at Q209 and R183 render Gα11 constitutively active and oncogenic, inducing metastasizing uveal melanoma in mouse models via constitutive MAPK activation, with R183 and Q209 mutants engaging distinct effector pathways (p38 versus p38/JNK/ERK) [PMID:21083380, PMID:26778290, PMID:29490280]. Constitutive signaling proceeds through PKC, which sustains MAPK, and parallel PI3K/AKT and Hippo/YAP pathways, such that combined PKC+MEK or MEK+PI3K inhibition produces synergistic tumor suppression [PMID:24141786, PMID:27308390, PMID:22733540]. Downstream, mutant Gα11 drives RasGRP3-dependent Ras activation and constitutively elevates IP3, creating a synthetic-lethal dependency on the IP3-degrading enzyme INPP5A whose loss triggers calcium-driven, p53-dependent apoptosis [PMID:29490280, PMID:38233483]. In endothelial cells, Gα11 mediates FGF2/VEGFA-stimulated migration via PLCβ3, and mosaic disease variants hyperactivate calcium signaling fueled by CRAC-channel calcium influx [PMID:29659033, PMID:37802293].","teleology":[{"year":1996,"claim":"Establishing the gene's structure and expression pattern provided the foundation for interpreting Gα11 as a broadly acting signaling subunit distinct from its tissue-restricted paralog.","evidence":"Genomic characterization and tissue expression analysis of murine Gna11/Gna15","pmids":["8838318"],"confidence":"Medium","gaps":["No functional signaling activity assayed","Human gene structure inferred from mouse"]},{"year":2010,"claim":"Identifying recurrent somatic Q209 and R183 mutations that constitutively activate MAPK and drive metastasizing tumors established GNA11 as a bona fide oncogene rather than a passenger.","evidence":"Sequencing of melanocytic neoplasms plus mutant-expressing mouse model with MAPK readout","pmids":["21083380"],"confidence":"High","gaps":["Effectors linking active Gα11 to MAPK not yet defined","Did not distinguish R183 vs Q209 signaling differences"]},{"year":2013,"claim":"Mapping an Egr-1 binding site in the GNA11 promoter addressed how Gα11 transcript levels are controlled.","evidence":"Promoter luciferase reporter, EMSA, and Egr-1 overexpression with mRNA quantification","pmids":["23802749"],"confidence":"Medium","gaps":["Physiological contexts driving Egr-1 regulation of GNA11 unknown","Relevance to disease states not tested"]},{"year":2014,"claim":"Functional dissection of CaSR mutation studies defined the CaSR-Gα11-PLC-calcium axis and showed germline mutations in either direction cause calcium-homeostasis disease.","evidence":"WES, expression of mutant vs wild-type Gα11 in HEK293-CaSR cells, calcium and ERK assays across FHH2 and ADH2 variants","pmids":["26729423","28833550","24823460"],"confidence":"High","gaps":["Precise structural basis of CaSR coupling not resolved here","In vivo parathyroid/renal mechanism inferred from cellular assays"]},{"year":2014,"claim":"Discovering PI3K/AKT activation and reciprocal MAPK-AKT crosstalk downstream of mutant Gα11 explained resistance to single-pathway inhibition and rationalized combination therapy.","evidence":"RNAi plus MEK and PI3K inhibitors with proteomic network analysis and apoptosis assays in genotyped UM cell lines","pmids":["22733540"],"confidence":"Medium","gaps":["Mechanism coupling Gα11 to PI3K not defined","Limited to cell lines"]},{"year":2014,"claim":"Implicating Hippo/YAP as a downstream effector broadened the mutant Gα11 signaling output beyond MAPK.","evidence":"Verteporfin (YAP inhibitor) treatment of Gq/11-mutant UM cells with tumor growth readout","pmids":["27308390"],"confidence":"Medium","gaps":["Single pharmacological method without genetic validation","Mechanism of YAP activation by Gα11 not dissected"]},{"year":2016,"claim":"Demonstrating mutation-site-specific effector engagement and dermal melanocytosis in vivo clarified that R183 and Q209 mutants drive distinct pathway repertoires and phenotypes.","evidence":"In vitro expression of R183C vs Q209L in human cells plus mitfa-driven mosaic zebrafish","pmids":["26778290"],"confidence":"High","gaps":["Functional consequence of differential p38/JNK/ERK activation untested","Link to tumor versus benign lesion outcome unclear"]},{"year":2017,"claim":"Identifying a PLC-binding hydrophobic cleft and rescuing loss-of-function with cinacalcet pinpointed the effector-coupling surface and a therapeutic strategy for FHH2.","evidence":"Homology modeling, site-directed mutagenesis, HEK293-CaSR calcium/ERK assays, in vivo cinacalcet treatment","pmids":["28833550"],"confidence":"High","gaps":["No experimental structure of the Gα11-PLC interface","Long-term in vivo efficacy not addressed"]},{"year":2018,"claim":"Identifying RasGRP3 as a required mediator connected mutant Gα11 to Ras activation, filling the gap between the G protein and MAPK output.","evidence":"Melanocyte-specific Q209L mouse model, transcriptomics, RasGRP3 knockdown in human and murine systems","pmids":["29490280"],"confidence":"High","gaps":["Mechanism of RasGRP3 activation by Gα11 not fully defined","Contribution relative to PKC/PI3K branches unquantified"]},{"year":2018,"claim":"Defining a Gα11 role in endothelial migration via PLCβ3 extended its function to vascular biology beyond melanoma and calcium homeostasis.","evidence":"siRNA knockdown in HUVECs with migration assay and phospho-PLCβ3 immunoblotting","pmids":["29659033"],"confidence":"Medium","gaps":["Single-lab knockdown without genetic rescue","Receptor coupling FGF2/VEGFA to Gα11 unclear"]},{"year":2021,"claim":"Finding GNA11 gain-of-function mutations co-occurring with CTNNB1 in aldosterone-producing adenomas broadened the oncogenic spectrum to adrenal endocrine tumors.","evidence":"WES/targeted sequencing plus adrenocortical cell transfections with aldosterone secretion and gene expression assays","pmids":["34385710"],"confidence":"High","gaps":["Mechanism of additive interaction with CTNNB1 not resolved","Signaling pathway driving aldosterone output not mapped"]},{"year":2022,"claim":"Comparative interactome analysis showed Gα11 and Gαq have distinct binding partners, with TET2 binding Gαq but not Gα11, indicating non-redundant downstream regulation.","evidence":"Tandem-affinity-purification, mass spectrometry, and reciprocal Co-IP","pmids":["35580369"],"confidence":"Medium","gaps":["Functional consequence of differential interactomes untested","Single-lab interactome"]},{"year":2023,"claim":"Showing that mosaic Gα11/Gαq variants hyperactivate calcium signaling via CRAC-channel influx, correctable by allele-specific silencing or CRAC inhibition, identified a druggable node in vascular disease.","evidence":"Two cellular mosaicism models, calcium assays, allele-specific siRNA, CRAC channel inhibitor","pmids":["37802293"],"confidence":"High","gaps":["In vivo efficacy of CRAC inhibition not established","Link between calcium signal and lesion phenotype not fully traced"]},{"year":2024,"claim":"Identifying INPP5A as a synthetic-lethal dependency revealed that mutant Gα11's constitutive IP3 production creates a vulnerability exploitable through IP3/calcium/p53-driven apoptosis.","evidence":"Genome-scale CRISPR screens, INPP5A knockdown in vitro and in vivo, IP3/IP4 and calcium measurement, p53-dependent apoptosis assays","pmids":["38233483"],"confidence":"High","gaps":["No INPP5A-targeting therapeutic demonstrated","Generalizability beyond p53-wild-type tumors unclear"]},{"year":null,"claim":"How the distinct effector branches (PKC/MAPK, PI3K/AKT, YAP, RasGRP3-Ras, IP3-calcium) are integrated and weighted to determine specific disease phenotypes across tissues remains unresolved.","evidence":"","pmids":[],"confidence":"High","gaps":["No unified quantitative model of branch contributions","No experimental structure of active Gα11 with effectors","Tissue-specific determinants of tumor vs endocrine vs vascular outcome unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[14,3,4,5]},{"term_id":"GO:0003924","term_label":"GTPase activity","supporting_discovery_ids":[4]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[5,14]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[14]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[14,0,1,16]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,6,10,14]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[10,16]}],"complexes":["heterotrimeric Gq/11 G protein"],"partners":["CASR","PLCB3","RASGRP3","INPP5A"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P29992","full_name":"Guanine nucleotide-binding protein subunit alpha-11","aliases":["Guanine nucleotide-binding protein G(y) subunit alpha"],"length_aa":359,"mass_kda":42.1,"function":"Guanine nucleotide-binding proteins (G proteins) function as transducers downstream of G protein-coupled receptors (GPCRs) in numerous signaling cascades (PubMed:31073061). The alpha chain contains the guanine nucleotide binding site and alternates between an active, GTP-bound state and an inactive, GDP-bound state (PubMed:31073061). Signaling by an activated GPCR promotes GDP release and GTP binding (PubMed:31073061). The alpha subunit has a low GTPase activity that converts bound GTP to GDP, thereby terminating the signal (PubMed:31073061). Both GDP release and GTP hydrolysis are modulated by numerous regulatory proteins (PubMed:31073061). Signaling is mediated via phospholipase C-beta-dependent inositol lipid hydrolysis for signal propagation: activates phospholipase C-beta: following GPCR activation, GNA11 activates PLC-beta (PLCB1, PLCB2, PLCB3 or PLCB4), leading to production of diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) (PubMed:31073061). Transduces FFAR4 signaling in response to long-chain fatty acids (LCFAs) (PubMed:27852822). Together with GNAQ, required for heart development (By similarity). In the respiratory epithelium, transmits OXGR1-dependent signals that lead to downstream intracellular Ca(2+) release and mucocilliary clearance of airborne pathogens","subcellular_location":"Cell membrane; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/P29992/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GNA11","classification":"Not Classified","n_dependent_lines":10,"n_total_lines":1208,"dependency_fraction":0.008278145695364239},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"GNB1","stoichiometry":10.0},{"gene":"RAB11A","stoichiometry":0.2},{"gene":"SLC16A1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/GNA11","total_profiled":1310},"omim":[{"mim_id":"620874","title":"ADHESION G PROTEIN-COUPLED RECEPTOR F5; ADGRF5","url":"https://www.omim.org/entry/620874"},{"mim_id":"618448","title":"G PROTEIN-COUPLED RECEPTOR 139; GPR139","url":"https://www.omim.org/entry/618448"},{"mim_id":"615706","title":"AURICULOCONDYLAR SYNDROME 3; ARCND3","url":"https://www.omim.org/entry/615706"},{"mim_id":"615650","title":"REGULATOR OF G PROTEIN SIGNALING 22; RGS22","url":"https://www.omim.org/entry/615650"},{"mim_id":"615361","title":"HYPOCALCEMIA, AUTOSOMAL DOMINANT 2; HYPOC2","url":"https://www.omim.org/entry/615361"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/GNA11"},"hgnc":{"alias_symbol":["FBH","FBH2","FHH2"],"prev_symbol":["HHC2"]},"alphafold":{"accession":"P29992","domains":[{"cath_id":"3.40.50.300","chopping":"44-66_186-349","consensus_level":"medium","plddt":94.8433,"start":44,"end":349},{"cath_id":"1.10.400.10","chopping":"68-180","consensus_level":"medium","plddt":97.615,"start":68,"end":180}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P29992","model_url":"https://alphafold.ebi.ac.uk/files/AF-P29992-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P29992-F1-predicted_aligned_error_v6.png","plddt_mean":92.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GNA11","jax_strain_url":"https://www.jax.org/strain/search?query=GNA11"},"sequence":{"accession":"P29992","fasta_url":"https://rest.uniprot.org/uniprotkb/P29992.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P29992/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P29992"}},"corpus_meta":[{"pmid":"21083380","id":"PMC_21083380","title":"Mutations in GNA11 in uveal melanoma.","date":"2010","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21083380","citation_count":1166,"is_preprint":false},{"pmid":"24141786","id":"PMC_24141786","title":"Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24141786","citation_count":162,"is_preprint":false},{"pmid":"26778290","id":"PMC_26778290","title":"Mosaic Activating Mutations in GNA11 and GNAQ Are Associated with Phakomatosis Pigmentovascularis and Extensive Dermal Melanocytosis.","date":"2016","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/26778290","citation_count":130,"is_preprint":false},{"pmid":"27058448","id":"PMC_27058448","title":"Somatic Activating Mutations in GNAQ and GNA11 Are Associated with Congenital Hemangioma.","date":"2016","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27058448","citation_count":127,"is_preprint":false},{"pmid":"22733540","id":"PMC_22733540","title":"Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.","date":"2012","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/22733540","citation_count":121,"is_preprint":false},{"pmid":"28120216","id":"PMC_28120216","title":"A somatic GNA11 mutation is associated with extremity capillary malformation and overgrowth.","date":"2017","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/28120216","citation_count":109,"is_preprint":false},{"pmid":"25304237","id":"PMC_25304237","title":"GNAQ and GNA11 mutations in uveal melanoma.","date":"2014","source":"Melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/25304237","citation_count":97,"is_preprint":false},{"pmid":"26645730","id":"PMC_26645730","title":"Melanomas Associated With Blue Nevi or Mimicking Cellular Blue Nevi: Clinical, Pathologic, and Molecular Study of 11 Cases Displaying a High Frequency of GNA11 Mutations, BAP1 Expression Loss, and a Predilection for the Scalp.","date":"2016","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26645730","citation_count":93,"is_preprint":false},{"pmid":"24423917","id":"PMC_24423917","title":"Mutation frequencies of GNAQ, GNA11, BAP1, SF3B1, EIF1AX and TERT in uveal melanoma: detection of an activating mutation in the TERT gene promoter in a single case of uveal melanoma.","date":"2014","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24423917","citation_count":87,"is_preprint":false},{"pmid":"23778528","id":"PMC_23778528","title":"Patient survival in uveal melanoma is not affected by oncogenic mutations in GNAQ and GNA11.","date":"2013","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23778528","citation_count":83,"is_preprint":false},{"pmid":"28809862","id":"PMC_28809862","title":"GNAQ and GNA11 mutations and downstream YAP activation in choroidal nevi.","date":"2017","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28809862","citation_count":76,"is_preprint":false},{"pmid":"12736724","id":"PMC_12736724","title":"FNBP2 gene on human chromosome 1q32.1 encodes ARHGAP family protein with FCH, FBH, RhoGAP and SH3 domains.","date":"2003","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12736724","citation_count":71,"is_preprint":false},{"pmid":"29490280","id":"PMC_29490280","title":"GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma.","date":"2018","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/29490280","citation_count":71,"is_preprint":false},{"pmid":"34385710","id":"PMC_34385710","title":"Somatic mutations of GNA11 and GNAQ in CTNNB1-mutant aldosterone-producing adenomas presenting in puberty, pregnancy or menopause.","date":"2021","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34385710","citation_count":69,"is_preprint":false},{"pmid":"24823460","id":"PMC_24823460","title":"Autosomal dominant hypoparathyroidism caused by germline mutation in GNA11: phenotypic and molecular characterization.","date":"2014","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/24823460","citation_count":64,"is_preprint":false},{"pmid":"12759536","id":"PMC_12759536","title":"Reduced expression of GNA11 and silencing of MCT1 in human breast cancers.","date":"2003","source":"Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/12759536","citation_count":55,"is_preprint":false},{"pmid":"24563540","id":"PMC_24563540","title":"The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.","date":"2014","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/24563540","citation_count":54,"is_preprint":false},{"pmid":"26399561","id":"PMC_26399561","title":"Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases.","date":"2015","source":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26399561","citation_count":53,"is_preprint":false},{"pmid":"22758774","id":"PMC_22758774","title":"GNA11 and N-RAS mutations: alternatives for MAPK pathway activating GNAQ mutations in primary melanocytic tumours of the central nervous system.","date":"2013","source":"Neuropathology and applied neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/22758774","citation_count":49,"is_preprint":false},{"pmid":"30204251","id":"PMC_30204251","title":"GNAS, GNAQ, and GNA11 alterations in patients with diverse cancers.","date":"2018","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30204251","citation_count":43,"is_preprint":false},{"pmid":"23634288","id":"PMC_23634288","title":"Ultradeep sequencing detects GNAQ and GNA11 mutations in cell-free DNA from plasma of patients with uveal melanoma.","date":"2013","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23634288","citation_count":43,"is_preprint":false},{"pmid":"31189994","id":"PMC_31189994","title":"High frequency of GNA14, GNAQ, and GNA11 mutations in cherry hemangioma: a histopathological and molecular study of 85 cases indicating GNA14 as the most commonly mutated gene in vascular neoplasms.","date":"2019","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/31189994","citation_count":39,"is_preprint":false},{"pmid":"27914687","id":"PMC_27914687","title":"BRAF, NRAS, KIT, TERT, GNAQ/GNA11 mutation profile analysis of head and neck mucosal melanomas: a study of 42 cases.","date":"2016","source":"Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/27914687","citation_count":39,"is_preprint":false},{"pmid":"26729423","id":"PMC_26729423","title":"A G-protein Subunit-α11 Loss-of-Function Mutation, Thr54Met, Causes Familial Hypocalciuric Hypercalcemia Type 2 (FHH2).","date":"2016","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/26729423","citation_count":36,"is_preprint":false},{"pmid":"28700778","id":"PMC_28700778","title":"Frequent GNAQ, GNA11, and EIF1AX Mutations in Iris Melanoma.","date":"2017","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/28700778","citation_count":35,"is_preprint":false},{"pmid":"28833550","id":"PMC_28833550","title":"Cinacalcet Rectifies Hypercalcemia in a Patient With Familial Hypocalciuric Hypercalcemia Type 2 (FHH2) Caused by a Germline Loss-of-Function Gα11 Mutation.","date":"2017","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/28833550","citation_count":34,"is_preprint":false},{"pmid":"27438697","id":"PMC_27438697","title":"Symptomatic Congenital Hemangioma and Congenital Hemangiomatosis Associated With a Somatic Activating Mutation in GNA11.","date":"2016","source":"JAMA dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/27438697","citation_count":34,"is_preprint":false},{"pmid":"26368812","id":"PMC_26368812","title":"Distribution of GNAQ and GNA11 Mutation Signatures in Uveal Melanoma Points to a Light Dependent Mutation Mechanism.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26368812","citation_count":33,"is_preprint":false},{"pmid":"32064597","id":"PMC_32064597","title":"GNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma.","date":"2020","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/32064597","citation_count":32,"is_preprint":false},{"pmid":"23599145","id":"PMC_23599145","title":"Identification of HRAS mutations and absence of GNAQ or GNA11 mutations in deep penetrating nevi.","date":"2013","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/23599145","citation_count":32,"is_preprint":false},{"pmid":"27148356","id":"PMC_27148356","title":"Gnaq and Gna11 in the Endothelin Signaling Pathway and Melanoma.","date":"2016","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27148356","citation_count":29,"is_preprint":false},{"pmid":"31707589","id":"PMC_31707589","title":"GNA11 joins GNAQ and GNA14 as a recurrently mutated gene in anastomosing hemangioma.","date":"2019","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31707589","citation_count":28,"is_preprint":false},{"pmid":"30763678","id":"PMC_30763678","title":"Ubiquitylome profiling of Parkin-null brain reveals dysregulation of calcium homeostasis factors ATP1A2, Hippocalcin and GNA11, reflected by altered firing of noradrenergic neurons.","date":"2019","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/30763678","citation_count":27,"is_preprint":false},{"pmid":"35715928","id":"PMC_35715928","title":"GNA11-mutated Sturge-Weber syndrome has distinct neurological and dermatological features.","date":"2022","source":"European journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/35715928","citation_count":26,"is_preprint":false},{"pmid":"8838318","id":"PMC_8838318","title":"Gene structure of murine Gna11 and Gna15: tandemly duplicated Gq class G protein alpha subunit genes.","date":"1996","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8838318","citation_count":26,"is_preprint":false},{"pmid":"35580369","id":"PMC_35580369","title":"In uveal melanoma Gα-protein GNA11 mutations convey a shorter disease-specific survival and are more strongly associated with loss of BAP1 and chromosomal alterations than Gα-protein GNAQ mutations.","date":"2022","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/35580369","citation_count":24,"is_preprint":false},{"pmid":"25280020","id":"PMC_25280020","title":"Oncogenic GNAQ and GNA11 mutations in uveal melanoma in Chinese.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25280020","citation_count":23,"is_preprint":false},{"pmid":"34040639","id":"PMC_34040639","title":"GNA14, GNA11, and GNAQ Mutations Are Frequent in Benign but Not Malignant Cutaneous Vascular Tumors.","date":"2021","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34040639","citation_count":23,"is_preprint":false},{"pmid":"31173078","id":"PMC_31173078","title":"Heterogeneity in Mitogen-Activated Protein Kinase (MAPK) Pathway Activation in Uveal Melanoma With Somatic GNAQ and GNA11 Mutations.","date":"2019","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/31173078","citation_count":22,"is_preprint":false},{"pmid":"27308390","id":"PMC_27308390","title":"YAP inhibition blocks uveal melanogenesis driven by GNAQ or GNA11 mutations.","date":"2014","source":"Molecular & cellular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27308390","citation_count":22,"is_preprint":false},{"pmid":"29209985","id":"PMC_29209985","title":"Frequent and Yet Unreported GNAQ and GNA11 Mutations are Found in Uveal Melanomas.","date":"2017","source":"Pathology oncology research : POR","url":"https://pubmed.ncbi.nlm.nih.gov/29209985","citation_count":21,"is_preprint":false},{"pmid":"37802293","id":"PMC_37802293","title":"GNAQ/GNA11 Mosaicism Causes Aberrant Calcium Signaling Susceptible to Targeted Therapeutics.","date":"2023","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/37802293","citation_count":18,"is_preprint":false},{"pmid":"28176280","id":"PMC_28176280","title":"Stepwise CaSR, AP2S1, and GNA11 sequencing in patients with suspected familial hypocalciuric hypercalcemia.","date":"2017","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/28176280","citation_count":18,"is_preprint":false},{"pmid":"27334330","id":"PMC_27334330","title":"Impaired growth and intracranial calcifications in autosomal dominant hypocalcemia caused by a GNA11 mutation.","date":"2016","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/27334330","citation_count":18,"is_preprint":false},{"pmid":"27913609","id":"PMC_27913609","title":"AP2S1 and GNA11 mutations - not a common cause of familial hypocalciuric hypercalcemia.","date":"2016","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/27913609","citation_count":16,"is_preprint":false},{"pmid":"31614358","id":"PMC_31614358","title":"Mutations of GNAQ, GNA11, SF3B1, EIF1AX, PLCB4 and CYSLTR in Uveal Melanoma in Chinese Patients.","date":"2019","source":"Ophthalmic research","url":"https://pubmed.ncbi.nlm.nih.gov/31614358","citation_count":16,"is_preprint":false},{"pmid":"29514290","id":"PMC_29514290","title":"The FBH family of bHLH transcription factors controls ACC synthase expression in sugarcane.","date":"2018","source":"Journal of experimental botany","url":"https://pubmed.ncbi.nlm.nih.gov/29514290","citation_count":14,"is_preprint":false},{"pmid":"23825798","id":"PMC_23825798","title":"Lack of GNAQ and GNA11 Germ-Line Mutations in Familial Melanoma Pedigrees with Uveal Melanoma or Blue Nevi.","date":"2013","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/23825798","citation_count":13,"is_preprint":false},{"pmid":"31394807","id":"PMC_31394807","title":"Do GNAQ and GNA11 Differentially Affect Inflammation and HLA Expression in Uveal Melanoma?","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31394807","citation_count":12,"is_preprint":false},{"pmid":"23650591","id":"PMC_23650591","title":"BRAF, GNAQ, and GNA11 mutations and copy number in pediatric low-grade glioma.","date":"2012","source":"FEBS open bio","url":"https://pubmed.ncbi.nlm.nih.gov/23650591","citation_count":12,"is_preprint":false},{"pmid":"28881731","id":"PMC_28881731","title":"Detection of BRAF, NRAS, KIT, GNAQ, GNA11 and MAP2K1/2 mutations in Russian melanoma patients using LNA PCR clamp and biochip analysis.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28881731","citation_count":12,"is_preprint":false},{"pmid":"38233483","id":"PMC_38233483","title":"INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomas.","date":"2024","source":"Nature cancer","url":"https://pubmed.ncbi.nlm.nih.gov/38233483","citation_count":11,"is_preprint":false},{"pmid":"32310862","id":"PMC_32310862","title":"Melanoma Ex Blue Nevus With GNA11 Mutation and BAP1 Loss: Case Report and Review of the Literature.","date":"2020","source":"The American Journal of dermatopathology","url":"https://pubmed.ncbi.nlm.nih.gov/32310862","citation_count":11,"is_preprint":false},{"pmid":"27239460","id":"PMC_27239460","title":"Investigation of Somatic GNAQ, GNA11, BAP1 and SF3B1 Mutations in Ophthalmic Melanocytomas.","date":"2016","source":"Ocular oncology and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/27239460","citation_count":11,"is_preprint":false},{"pmid":"24137342","id":"PMC_24137342","title":"Mutational analysis of the GNA11, MMP27, FGD1, TRRAP and GRM3 genes in thyroid cancer.","date":"2013","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/24137342","citation_count":11,"is_preprint":false},{"pmid":"36970776","id":"PMC_36970776","title":"GNA11 Variants Identified in Patients with Hypercalcemia or Hypocalcemia.","date":"2023","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/36970776","citation_count":10,"is_preprint":false},{"pmid":"18330691","id":"PMC_18330691","title":"Cloning, expression pattern, chromosomal localization, and evolution analysis of Porcine gnaq, gna11, and gna14.","date":"2008","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18330691","citation_count":10,"is_preprint":false},{"pmid":"37750536","id":"PMC_37750536","title":"Papillary Hemangioma Harbors Somatic GNA11 and GNAQ Mutations.","date":"2023","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/37750536","citation_count":9,"is_preprint":false},{"pmid":"26275246","id":"PMC_26275246","title":"BRAF, KIT, NRAS, GNAQ and GNA11 mutation analysis in cutaneous melanomas in Turkish population.","date":"2015","source":"Indian journal of pathology & microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/26275246","citation_count":9,"is_preprint":false},{"pmid":"35351629","id":"PMC_35351629","title":"Cutis marmorata telangiectatica congenita being caused by postzygotic GNA11 mutations.","date":"2022","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35351629","citation_count":9,"is_preprint":false},{"pmid":"31310691","id":"PMC_31310691","title":"Oral pyogenic granulomas show MAPK/ERK signaling pathway activation, which occurs independently of BRAF, KRAS, HRAS, NRAS, GNA11, and GNA14 mutations.","date":"2019","source":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31310691","citation_count":9,"is_preprint":false},{"pmid":"26825879","id":"PMC_26825879","title":"GNA11 Mutation in a Patient With Cutaneous Origin Melanoma: A Case Report.","date":"2016","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26825879","citation_count":9,"is_preprint":false},{"pmid":"28982892","id":"PMC_28982892","title":"Uveal Melanoma: GNAQ and GNA11 Mutations in a Greek Population.","date":"2017","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/28982892","citation_count":8,"is_preprint":false},{"pmid":"29659033","id":"PMC_29659033","title":"GNA11 differentially mediates fibroblast growth factor 2- and vascular endothelial growth factor A-induced cellular responses in human fetoplacental endothelial cells.","date":"2018","source":"The Journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/29659033","citation_count":8,"is_preprint":false},{"pmid":"34345456","id":"PMC_34345456","title":"S-100-negative, GNA11 mutation-positive intramedullary meningeal melanocytoma of the thoracic spine: A radiographic challenge and histologic anomaly.","date":"2021","source":"Surgical neurology international","url":"https://pubmed.ncbi.nlm.nih.gov/34345456","citation_count":8,"is_preprint":false},{"pmid":"34750314","id":"PMC_34750314","title":"GNA11 Mutation in an Intracranial Melanocytoma with Orbital Involvement and Nevus of Ota.","date":"2022","source":"Ophthalmic plastic and reconstructive surgery","url":"https://pubmed.ncbi.nlm.nih.gov/34750314","citation_count":6,"is_preprint":false},{"pmid":"24797109","id":"PMC_24797109","title":"Subcellular distribution patterns and elevated expression of GNA11 and GNA14 proteins in the lungs of humans with pulmonary arterial hypertension.","date":"2014","source":"Cell biology international","url":"https://pubmed.ncbi.nlm.nih.gov/24797109","citation_count":6,"is_preprint":false},{"pmid":"28248732","id":"PMC_28248732","title":"The Role of Mutation Rates of GNAQ or GNA11 in Cases of Uveal Melanoma in Japan.","date":"2018","source":"Applied immunohistochemistry & molecular morphology : AIMM","url":"https://pubmed.ncbi.nlm.nih.gov/28248732","citation_count":6,"is_preprint":false},{"pmid":"38505749","id":"PMC_38505749","title":"Double somatic mutations in CTNNB1 and GNA11 in an aldosterone-producing adenoma.","date":"2024","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/38505749","citation_count":5,"is_preprint":false},{"pmid":"35693877","id":"PMC_35693877","title":"Mutation spectrum in GNAQ and GNA11 in Chinese uveal melanoma.","date":"2019","source":"Precision clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35693877","citation_count":5,"is_preprint":false},{"pmid":"35642348","id":"PMC_35642348","title":"BRAF, NRAS, KIT, TERT, GNAQ/GNA11 Mutation Profile and Histomorphological Analysis of Anorectal Melanomas: A Clinicopathologic Study.","date":"2023","source":"Turk patoloji dergisi","url":"https://pubmed.ncbi.nlm.nih.gov/35642348","citation_count":4,"is_preprint":false},{"pmid":"36835134","id":"PMC_36835134","title":"Autoantibodies to PAX5, PTCH1, and GNA11 as Serological Biomarkers in the Detection of Hepatocellular Carcinoma in Hispanic Americans.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36835134","citation_count":4,"is_preprint":false},{"pmid":"34568004","id":"PMC_34568004","title":"Identification and Evaluation of Autoantibody to a Novel Tumor-Associated Antigen GNA11 as a Biomarker in Esophageal Squamous Cell Carcinoma.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34568004","citation_count":4,"is_preprint":false},{"pmid":"23464620","id":"PMC_23464620","title":"Skin metastases in metastatic uveal melanoma: GNAQ/GNA11 mutational analysis as a valuable tool.","date":"2013","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/23464620","citation_count":4,"is_preprint":false},{"pmid":"23802749","id":"PMC_23802749","title":"Cloning and characterization of the GNA11 promoter and its regulation by early growth response 1.","date":"2013","source":"Basic & clinical pharmacology & toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/23802749","citation_count":3,"is_preprint":false},{"pmid":"34260077","id":"PMC_34260077","title":"Mixed vascular naevus syndrome: report of three children with somatic GNA11 mutation and new systemic associations.","date":"2021","source":"Clinical and experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/34260077","citation_count":3,"is_preprint":false},{"pmid":"35777808","id":"PMC_35777808","title":"The Youngest Infant to Be Diagnosed with Autosomal Dominant Hypocalcemia Type 2 Harboring a Novel Variant of GNA11: A Case Study and Literature Review.","date":"2022","source":"Annals of clinical and laboratory science","url":"https://pubmed.ncbi.nlm.nih.gov/35777808","citation_count":3,"is_preprint":false},{"pmid":"28012237","id":"PMC_28012237","title":"Sporadic melanotic schwannoma with overlapping features of melanocytoma bearing a GNA11 mutation in an adolescent girl.","date":"2016","source":"Pediatric blood & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28012237","citation_count":3,"is_preprint":false},{"pmid":"39654261","id":"PMC_39654261","title":"Phenotypic Spectrum of GNA11 R183C Mosaicism.","date":"2024","source":"Pediatric dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/39654261","citation_count":2,"is_preprint":false},{"pmid":"38910853","id":"PMC_38910853","title":"Somatic GNA11/GNAQ variants in a cohort of Chinese children with phakomatosis pigmentovascularis.","date":"2024","source":"Pediatric investigation","url":"https://pubmed.ncbi.nlm.nih.gov/38910853","citation_count":1,"is_preprint":false},{"pmid":"41403972","id":"PMC_41403972","title":"Uveal Melanocytoma without GNAQ/GNA11 Mutations.","date":"2025","source":"Ocular oncology and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/41403972","citation_count":0,"is_preprint":false},{"pmid":"37284406","id":"PMC_37284406","title":"Primary Mucosal Melanoma of the Lip With GNA11 Mutation in a 23-Year-Old Pregnant Woman.","date":"2023","source":"Cureus","url":"https://pubmed.ncbi.nlm.nih.gov/37284406","citation_count":0,"is_preprint":false},{"pmid":"41240382","id":"PMC_41240382","title":"A novel homozygous c.301T > C, p.Y101H variant in the GNA11 gene is implicated in familial hypocalciuric hypercalcemia type 2 in a proband with the heterozygous variant present in mother and father - A case report.","date":"2025","source":"Scandinavian journal of clinical and laboratory investigation","url":"https://pubmed.ncbi.nlm.nih.gov/41240382","citation_count":0,"is_preprint":false},{"pmid":"31887832","id":"PMC_31887832","title":"[GNA11 gene rs11084997 polymorphisms might be associated with risk of adult-onset non-surgical hypoparathyroidism].","date":"2020","source":"Zhonghua nei ke za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/31887832","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.10.07.681001","title":"Roles of G-protein coupled receptors and mechanosensitive ion channels in pressure-induced chronotropy of lymphatic vessels","date":"2025-10-07","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.07.681001","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.05.04.652102","title":"Context-Dependent Synergism and Antagonism between IGF2BP1/3 and METTL3/14 in m6A-mediated mRNA regulation","date":"2025-05-04","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.04.652102","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.01.24.633441","title":"Clinico-genomic features predict distinct metastatic phenotypes in cutaneous melanoma","date":"2025-01-27","source":"bioRxiv","url":"https://doi.org/10.1101/2025.01.24.633441","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.11.25.625282","title":"Oncogenic GNAQ/11-induced remodeling of the IP3/Calcium signaling pathway protects Uveal Melanoma against Calcium-driven cell death","date":"2024-11-28","source":"bioRxiv","url":"https://doi.org/10.1101/2024.11.25.625282","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.09.18.613756","title":"Examination of INPP5A in uveal melanoma uncovers novel calcium transients","date":"2024-09-22","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.18.613756","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48908,"output_tokens":4648,"usd":0.108222,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":12802,"output_tokens":4312,"usd":0.085905,"stage2_stop_reason":"end_turn"},"total_usd":0.194127,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2010,\n      \"finding\": \"Somatic mutations at Q209 and R183 in GNA11 (encoding Gα11, an alpha subunit of heterotrimeric G proteins) constitutively activate the MAPK pathway and induce spontaneously metastasizing tumors in a mouse model, establishing GNA11 as an oncogene in uveal melanoma.\",\n      \"method\": \"Sequencing of melanocytic neoplasms, mouse model with GNA11-mutant expression, MAPK pathway activation assay\",\n      \"journal\": \"The New England journal of medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mutant gene expression in mouse model with defined phenotypic readout (metastasizing tumors) and MAPK pathway activation, replicated across multiple labs in subsequent work\",\n      \"pmids\": [\"21083380\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"PKC activation is a consequence of GNAQ or GNA11 mutation in uveal melanoma, and PKC inhibition suppresses both PKC and MAPK signaling, establishing PKC as a key effector downstream of mutant GNA11. PKC inhibitors alone cannot sustain MAPK suppression, but combined PKC + MEK inhibition produces synergistic anti-tumor effects in vitro and in vivo.\",\n      \"method\": \"Cell line signaling assays with PKC inhibitors (AEB071, AHT956) and MEK inhibitors (PD0325901, MEK162), allograft and xenograft mouse models\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (in vitro signaling, in vivo xenograft), consistent findings across multiple inhibitors and models\",\n      \"pmids\": [\"24141786\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In vitro expression of mutant GNA11(R183C) activates the p38 MAPK signaling pathway, while GNA11(Q209L) activates p38, JNK, and ERK pathways, demonstrating differential downstream signaling depending on mutation site. Mosaic zebrafish expressing GNA11(R183C) under the mitfa promoter develop extensive dermal melanocytosis.\",\n      \"method\": \"In vitro expression of mutant GNA11 in human cell lines, transgenic zebrafish model\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct functional assays in human cell lines plus in vivo zebrafish model with specific phenotypic readout, multiple orthogonal methods\",\n      \"pmids\": [\"26778290\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"A germline gain-of-function mutation in GNA11 (R60L) causes autosomal dominant hypoparathyroidism. Functional studies in HEK293 cells stably expressing CaSR showed that R60L Gα11 increases intracellular calcium accumulation in response to extracellular calcium with a significantly decreased EC50, indicating enhanced coupling of the calcium-sensing receptor to Gα11 signaling. R60L was less effective than oncogenic Q209L as an activator of the MAPK pathway.\",\n      \"method\": \"Whole-exome sequencing, functional expression of wild-type and mutant Gα11 in HEK293-CaR cells, intracellular calcium measurement\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct in vitro functional assay with mutant vs. wild-type comparison in CaSR-expressing cells, single lab but multiple parameters measured\",\n      \"pmids\": [\"24823460\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"A loss-of-function GNA11 mutation (Thr54Met), located at the interface between the Gα11 helical and GTPase domains, impairs GDP binding and interdomain interactions. Expression in HEK293 cells stably expressing CaSR demonstrated rightward shift of the calcium concentration-response curve (increased EC50), establishing loss-of-function as the mechanism for FHH2.\",\n      \"method\": \"Homology modeling, functional expression in HEK293-CaSR cells, flow cytometry for intracellular calcium measurement\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — structural modeling plus in vitro functional assay with mutant vs. wild-type, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"26729423\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"A loss-of-function GNA11 mutation (Phe220Ser) disrupts a hydrophobic cleft region of Gα11 that is critical for binding to and activating phospholipase C (PLC). Expression of mutant Gα11 in CaSR-expressing HEK293 cells impaired CaSR-mediated intracellular calcium and ERK1/2 MAPK signaling. Engineered mutagenesis of the hydrophobic cleft confirmed its role in PLC activation. The loss-of-function was rescued by cinacalcet (a CaSR-positive allosteric modulator) both in vitro and in vivo.\",\n      \"method\": \"Homology modeling, transient transfection of mutant vs. wild-type Gα11 in HEK293-CaSR cells, calcium signaling assay, ERK phosphorylation assay, site-directed mutagenesis, in vivo cinacalcet treatment\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — structural modeling + mutagenesis + in vitro reconstitution + in vivo validation, multiple orthogonal methods in single rigorous study\",\n      \"pmids\": [\"28833550\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"GNA11(Q209L) mouse model (melanocyte-specific expression) develops uveal melanoma-like pigmented neoplastic lesions from melanocytes in the eye, skin, leptomeninges, lymph nodes, and lungs. Transcriptome analysis identified RasGRP3 as specifically expressed in GNAQ/GNA11-driven melanomas; RasGRP3 is required for GNAQ/GNA11-driven Ras activation and tumorigenesis in human UM cell lines and murine models.\",\n      \"method\": \"Transgenic mouse model (GNA11Q209L melanocyte-specific), integrative transcriptome analysis, RasGRP3 knockdown in human UM cell lines and murine models\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic model plus loss-of-function in human cell lines with defined molecular readout (Ras activation), multiple orthogonal methods\",\n      \"pmids\": [\"29490280\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"GNA11 knockdown in human fetoplacental endothelial cells (HUVECs under 3% O2) significantly reduces FGF2- and VEGFA-stimulated cell migration but not proliferation or permeability. GNA11 siRNA also elevated FGF2- and VEGFA-induced phosphorylation of phospholipase C-β3 (PLCβ3) at S537, indicating that GNA11 mediates FGF2/VEGFA-induced endothelial migration partly by modulating PLCβ3 activation.\",\n      \"method\": \"siRNA knockdown of GNA11 in HUVECs, cell migration assay, phospho-PLCβ3 and phospho-ERK1/2 immunoblotting\",\n      \"journal\": \"The Journal of physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — siRNA knockdown with defined cellular phenotype (migration) and molecular readout (PLCβ3 phosphorylation), single lab, two orthogonal readouts\",\n      \"pmids\": [\"29659033\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Somatic gain-of-function mutations of GNA11 (Q209H, Q209P, Q209L) co-occur with CTNNB1 mutations in aldosterone-producing adenomas (APAs). Transfections of adrenocortical cells demonstrated additive effects of GNA11 and CTNNB1 mutations on aldosterone secretion and expression of genes upregulated in double-mutant APAs, including LHCGR.\",\n      \"method\": \"Whole-exome sequencing, targeted sequencing, transfection of adrenocortical cells with mutant constructs, aldosterone secretion assay, gene expression analysis\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vitro functional transfection assays showing additive effects on aldosterone secretion, multiple methods and cohort-level validation\",\n      \"pmids\": [\"34385710\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Disease-causing GNAQ/GNA11 mosaic variants hyperactivate constitutive and ligand-induced intracellular calcium signaling in endothelial cells. The aberrant ligand-activated calcium signal is fueled by extracellular calcium influx through calcium-release-activated (CRAC) channels. siRNA silencing of the variant allele corrects both signals; a CRAC channel inhibitor rescues the ligand-activated signal.\",\n      \"method\": \"Two cellular models of GNAQ/GNA11 mosaicism, calcium signaling assays, allele-specific siRNA, CRAC channel inhibitor treatment\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal interventions (allele-specific siRNA, small molecule inhibitor), two cellular models, defined molecular mechanism identified\",\n      \"pmids\": [\"37802293\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"INPP5A is a synthetic lethal dependency in GNAQ/GNA11-mutant uveal melanoma cells. Mutant GNA11/GNAQ cells constitutively produce high levels of IP3; suppression of INPP5A causes IP3 accumulation, hyperactivation of IP3-receptor signaling, increased cytosolic calcium, and p53-dependent apoptosis. GNA11/GNAQ inhibition abolishes elevated IP4 levels (a biomarker of IP3 production) and correlates with INPP5A sensitivity.\",\n      \"method\": \"Genome-scale CRISPR screens, computational cancer dependency analyses, INPP5A knockdown in UM cell lines and in vivo, IP3/IP4 measurement, calcium assay, p53-dependent apoptosis assay\",\n      \"journal\": \"Nature cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-scale CRISPR screen plus in vitro and in vivo validation with defined molecular mechanism (IP3-receptor-Ca2+-p53 axis), multiple orthogonal methods\",\n      \"pmids\": [\"38233483\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"YAP (Yes-associated protein) inhibition with verteporfin blocks tumor growth of Gq/11-mutated uveal melanoma cells, implicating the Hippo/YAP pathway as a downstream effector of mutant GNA11/GNAQ.\",\n      \"method\": \"YAP inhibitor (verteporfin) treatment of GNA11/GNAQ-mutant UM cells, tumor growth assay\",\n      \"journal\": \"Molecular & cellular oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — pharmacological inhibition of downstream effector with tumor growth readout, limited mechanistic dissection, single method\",\n      \"pmids\": [\"27308390\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The GNA11 promoter contains a functional binding site for the transcription factor Egr-1 at nt-475/-445. Egr-1 expression increases GNA11 promoter activity >2-fold and elevates Gα11 mRNA levels, establishing Egr-1 as a transcriptional regulator of GNA11.\",\n      \"method\": \"Promoter cloning, luciferase reporter assay with deletion constructs, electrophoretic mobility shift assay (EMSA), Egr-1 expression plasmid transfection, real-time PCR\",\n      \"journal\": \"Basic & clinical pharmacology & toxicology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA plus reporter assay plus mRNA quantification, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"23802749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Murine Gna11 and Gna15 are tandemly duplicated genes on mouse chromosome 10, spanning 43 kb with 6 kb intergenic region. The coding sequence of Gna11 is contained in seven exons with no evidence for alternative splicing. Gna11 is ubiquitously expressed, whereas Gna15 is restricted to hematopoietic cells.\",\n      \"method\": \"Gene structure characterization, genomic DNA sequencing, expression analysis, phylogenetic analysis\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct genomic characterization with expression analysis across tissues, single lab but foundational structural characterization\",\n      \"pmids\": [\"8838318\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"GNA11-encoded Gα11 couples the calcium-sensing receptor (CaSR) to phospholipase C (PLC)-mediated intracellular calcium signaling and MAPK signaling in parathyroid cells and kidneys to regulate PTH release and urinary calcium excretion. Loss-of-function mutations in Gα11 result in familial hypocalciuric hypercalcemia type 2 (FHH2).\",\n      \"method\": \"Genetic sequencing, functional expression in HEK293-CaSR cells, intracellular calcium assay, ERK signaling assay\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — functional coupling of CaSR-Gα11-PLC-calcium axis demonstrated in multiple FHH2 mutation studies with consistent results across multiple labs\",\n      \"pmids\": [\"26729423\", \"28833550\", \"24823460\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"GNAQ and GNA11 proteins have different protein interaction partners as determined by tandem-affinity-purification and mass spectrometry. Specifically, TET2 (Tet Methylcytosine Dioxygenase 2, a DNA demethylation enzyme) physically interacts with GNAQ but not with GNA11, as confirmed by immunoprecipitation, suggesting differential regulation of DNA methylation by the two G-proteins.\",\n      \"method\": \"Tandem-affinity-purification, mass spectrometry, immunoprecipitation\",\n      \"journal\": \"European journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP plus mass spectrometry interactome, single lab, two orthogonal methods supporting differential binding\",\n      \"pmids\": [\"35580369\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"GNA11-mutant uveal melanoma cells show activation of both PKC/MAPK and PI3K/AKT pathways downstream of mutant GNAQ/GNA11. Reciprocal activation of MAPK and AKT is observed upon MEK or PI3K inhibition, respectively. Combined MEK + PI3K inhibition induces apoptosis in a GNAQ/11 mutant-dependent manner.\",\n      \"method\": \"RNA interference, MEK inhibitor (GSK1120212) and PI3K inhibitor (GSK2126458) treatment, proteomic network analysis, apoptosis assay in genotyped UM cell lines\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNAi plus pharmacological inhibition with proteomic analysis, multiple cell lines with defined mutation status\",\n      \"pmids\": [\"22733540\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GNA11 encodes Gα11, a ubiquitously expressed alpha subunit of heterotrimeric Gq-class G proteins that couples the calcium-sensing receptor (and other GPCRs) to phospholipase C-β, generating IP3 and DAG to activate intracellular calcium signaling, PKC/MAPK, PI3K/AKT, and YAP pathways; somatic gain-of-function mutations at Q209 or R183 constitutively activate these cascades to drive uveal melanoma and vascular tumors via RasGRP3-mediated Ras activation and INPP5A-regulated IP3/calcium homeostasis, while germline loss-of-function mutations impair CaSR-Gα11-PLC coupling to cause familial hypocalciuric hypercalcemia type 2 (FHH2) and germline gain-of-function mutations cause autosomal dominant hypocalcemia type 2 (ADH2).\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"GNA11 encodes Gα11, a ubiquitously expressed alpha subunit of a heterotrimeric Gq-class G protein that couples the calcium-sensing receptor (CaSR) and other GPCRs to phospholipase C, driving intracellular calcium and MAPK signaling [#13, #14]. Through a hydrophobic cleft required for PLC binding and activation, Gα11 transduces CaSR signaling in parathyroid and kidney cells to control PTH release and urinary calcium excretion; loss-of-function mutations (Thr54Met, Phe220Ser) shift the calcium response curve rightward and cause familial hypocalciuric hypercalcemia type 2, while a gain-of-function mutation (R60L) lowers the EC50 for calcium and causes autosomal dominant hypoparathyroidism [#3, #4, #5, #14]. Somatic gain-of-function mutations at Q209 and R183 render Gα11 constitutively active and oncogenic, inducing metastasizing uveal melanoma in mouse models via constitutive MAPK activation, with R183 and Q209 mutants engaging distinct effector pathways (p38 versus p38/JNK/ERK) [#0, #2, #6]. Constitutive signaling proceeds through PKC, which sustains MAPK, and parallel PI3K/AKT and Hippo/YAP pathways, such that combined PKC+MEK or MEK+PI3K inhibition produces synergistic tumor suppression [#1, #11, #16]. Downstream, mutant Gα11 drives RasGRP3-dependent Ras activation and constitutively elevates IP3, creating a synthetic-lethal dependency on the IP3-degrading enzyme INPP5A whose loss triggers calcium-driven, p53-dependent apoptosis [#6, #10]. In endothelial cells, Gα11 mediates FGF2/VEGFA-stimulated migration via PLCβ3, and mosaic disease variants hyperactivate calcium signaling fueled by CRAC-channel calcium influx [#7, #9].\"\n  ,\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Establishing the gene's structure and expression pattern provided the foundation for interpreting Gα11 as a broadly acting signaling subunit distinct from its tissue-restricted paralog.\",\n      \"evidence\": \"Genomic characterization and tissue expression analysis of murine Gna11/Gna15\",\n      \"pmids\": [\"8838318\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No functional signaling activity assayed\", \"Human gene structure inferred from mouse\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identifying recurrent somatic Q209 and R183 mutations that constitutively activate MAPK and drive metastasizing tumors established GNA11 as a bona fide oncogene rather than a passenger.\",\n      \"evidence\": \"Sequencing of melanocytic neoplasms plus mutant-expressing mouse model with MAPK readout\",\n      \"pmids\": [\"21083380\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Effectors linking active Gα11 to MAPK not yet defined\", \"Did not distinguish R183 vs Q209 signaling differences\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Mapping an Egr-1 binding site in the GNA11 promoter addressed how Gα11 transcript levels are controlled.\",\n      \"evidence\": \"Promoter luciferase reporter, EMSA, and Egr-1 overexpression with mRNA quantification\",\n      \"pmids\": [\"23802749\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological contexts driving Egr-1 regulation of GNA11 unknown\", \"Relevance to disease states not tested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Functional dissection of CaSR mutation studies defined the CaSR-Gα11-PLC-calcium axis and showed germline mutations in either direction cause calcium-homeostasis disease.\",\n      \"evidence\": \"WES, expression of mutant vs wild-type Gα11 in HEK293-CaSR cells, calcium and ERK assays across FHH2 and ADH2 variants\",\n      \"pmids\": [\"26729423\", \"28833550\", \"24823460\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise structural basis of CaSR coupling not resolved here\", \"In vivo parathyroid/renal mechanism inferred from cellular assays\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Discovering PI3K/AKT activation and reciprocal MAPK-AKT crosstalk downstream of mutant Gα11 explained resistance to single-pathway inhibition and rationalized combination therapy.\",\n      \"evidence\": \"RNAi plus MEK and PI3K inhibitors with proteomic network analysis and apoptosis assays in genotyped UM cell lines\",\n      \"pmids\": [\"22733540\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism coupling Gα11 to PI3K not defined\", \"Limited to cell lines\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Implicating Hippo/YAP as a downstream effector broadened the mutant Gα11 signaling output beyond MAPK.\",\n      \"evidence\": \"Verteporfin (YAP inhibitor) treatment of Gq/11-mutant UM cells with tumor growth readout\",\n      \"pmids\": [\"27308390\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single pharmacological method without genetic validation\", \"Mechanism of YAP activation by Gα11 not dissected\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrating mutation-site-specific effector engagement and dermal melanocytosis in vivo clarified that R183 and Q209 mutants drive distinct pathway repertoires and phenotypes.\",\n      \"evidence\": \"In vitro expression of R183C vs Q209L in human cells plus mitfa-driven mosaic zebrafish\",\n      \"pmids\": [\"26778290\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of differential p38/JNK/ERK activation untested\", \"Link to tumor versus benign lesion outcome unclear\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identifying a PLC-binding hydrophobic cleft and rescuing loss-of-function with cinacalcet pinpointed the effector-coupling surface and a therapeutic strategy for FHH2.\",\n      \"evidence\": \"Homology modeling, site-directed mutagenesis, HEK293-CaSR calcium/ERK assays, in vivo cinacalcet treatment\",\n      \"pmids\": [\"28833550\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No experimental structure of the Gα11-PLC interface\", \"Long-term in vivo efficacy not addressed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identifying RasGRP3 as a required mediator connected mutant Gα11 to Ras activation, filling the gap between the G protein and MAPK output.\",\n      \"evidence\": \"Melanocyte-specific Q209L mouse model, transcriptomics, RasGRP3 knockdown in human and murine systems\",\n      \"pmids\": [\"29490280\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of RasGRP3 activation by Gα11 not fully defined\", \"Contribution relative to PKC/PI3K branches unquantified\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defining a Gα11 role in endothelial migration via PLCβ3 extended its function to vascular biology beyond melanoma and calcium homeostasis.\",\n      \"evidence\": \"siRNA knockdown in HUVECs with migration assay and phospho-PLCβ3 immunoblotting\",\n      \"pmids\": [\"29659033\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab knockdown without genetic rescue\", \"Receptor coupling FGF2/VEGFA to Gα11 unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Finding GNA11 gain-of-function mutations co-occurring with CTNNB1 in aldosterone-producing adenomas broadened the oncogenic spectrum to adrenal endocrine tumors.\",\n      \"evidence\": \"WES/targeted sequencing plus adrenocortical cell transfections with aldosterone secretion and gene expression assays\",\n      \"pmids\": [\"34385710\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of additive interaction with CTNNB1 not resolved\", \"Signaling pathway driving aldosterone output not mapped\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Comparative interactome analysis showed Gα11 and Gαq have distinct binding partners, with TET2 binding Gαq but not Gα11, indicating non-redundant downstream regulation.\",\n      \"evidence\": \"Tandem-affinity-purification, mass spectrometry, and reciprocal Co-IP\",\n      \"pmids\": [\"35580369\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of differential interactomes untested\", \"Single-lab interactome\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showing that mosaic Gα11/Gαq variants hyperactivate calcium signaling via CRAC-channel influx, correctable by allele-specific silencing or CRAC inhibition, identified a druggable node in vascular disease.\",\n      \"evidence\": \"Two cellular mosaicism models, calcium assays, allele-specific siRNA, CRAC channel inhibitor\",\n      \"pmids\": [\"37802293\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo efficacy of CRAC inhibition not established\", \"Link between calcium signal and lesion phenotype not fully traced\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identifying INPP5A as a synthetic-lethal dependency revealed that mutant Gα11's constitutive IP3 production creates a vulnerability exploitable through IP3/calcium/p53-driven apoptosis.\",\n      \"evidence\": \"Genome-scale CRISPR screens, INPP5A knockdown in vitro and in vivo, IP3/IP4 and calcium measurement, p53-dependent apoptosis assays\",\n      \"pmids\": [\"38233483\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No INPP5A-targeting therapeutic demonstrated\", \"Generalizability beyond p53-wild-type tumors unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the distinct effector branches (PKC/MAPK, PI3K/AKT, YAP, RasGRP3-Ras, IP3-calcium) are integrated and weighted to determine specific disease phenotypes across tissues remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No unified quantitative model of branch contributions\", \"No experimental structure of active Gα11 with effectors\", \"Tissue-specific determinants of tumor vs endocrine vs vascular outcome unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [14, 3, 4, 5]},\n      {\"term_id\": \"GO:0003924\", \"supporting_discovery_ids\": [4]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [5, 14]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [14]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [14, 0, 1, 16]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 6, 10, 14]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [10, 16]}\n    ],\n    \"complexes\": [\"heterotrimeric Gq/11 G protein\"],\n    \"partners\": [\"CaSR\", \"PLCB3\", \"RasGRP3\", \"INPP5A\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":6,"faith_pct":83.33333333333333}}